Molecular characterization and biomarker identification in paediatric B‐cell acute lymphoblastic leukaemia
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Yu Du und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplasm, Residual, Mutation, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
B‐cell acute lymphoblastic leukaemia (B‐ALL) is the most prevalent hematologic malignancy in children and a leading cause of mortality. Managing B‐ALL remains challenging due to its heterogeneity and relapse risk. This study aimed to delineate the molecular features of paediatric B‐ALL and explore the clinical utility of circulating tumour DNA (ctDNA). We analysed 146 patients with paediatric B‐ALL who received systemic chemotherapy. The mutational landscape was profiled in bone marrow (BM) and plasma samples using next‐generation sequencing. Minimal residual disease (MRD) testing on day 19 of induction therapy evaluated treatment efficacy. RNA sequencing identified gene fusions in 61% of patients, including 37 novel fusions. Specifically, the KMT2A ‐ TRIM29 novel fusion was validated in a boy who responded well to initial therapy but relapsed after 1 year. Elevated mutation counts and maximum variant allele frequency in baseline BM were associated with significantly poorer chemotherapy response ( p = 0.0012 and 0.028, respectively). MRD‐negative patients exhibited upregulation of immune‐related pathways ( p < 0.01) and increased CD8 + T cell infiltration ( p = 0.047). Baseline plasma ctDNA exhibited high mutational concordance with the paired BM samples and was significantly associated with chemotherapy efficacy. These findings suggest that ctDNA and BM profiling offer promising prognostic insights for paediatric B‐ALL management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Precision Medical Center, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Pediatric Hematological Tumor Disease Laboratory, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, China.
ORCID-Profile: Yu Du
Zitieren
APA
Du, Y., Zhang, X., Sun, M., Yang, L., Long, F., Qi, S., Luo, L., Lv, X., Wang, C., Wu, X., Zhu, L., Ou, Q., & Xiong, H. (2024). Molecular characterization and biomarker identification in paediatric B‐cell acute lymphoblastic leukaemia. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70126
Vancouver
Du Y, Zhang X, Sun M, Yang L, Long F, Qi S, et al. Molecular characterization and biomarker identification in paediatric B‐cell acute lymphoblastic leukaemia. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70126
BibTeX
@article{Du2024,
author = {Du, Yu and Zhang, Xiankai and Sun, Ming and Yang, Li and Long, Fei and Qi, Shanshan and Luo, Linlin and Lv, Xiaoyan and Wang, Chenxuan and Wu, Xiaoying and Zhu, Liuqing and Ou, Qiuxiang and Xiong, Hao},
title = {Molecular characterization and biomarker identification in paediatric B‐cell acute lymphoblastic leukaemia},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70126}
}
EUVIMED